Broad cancer coalition tries new way to increase access to meds

20 May 2022
atom_big

A new coalition in oncology will forge an innovative model of collaboration with the goal of boosting access to cancer medicines.

Dubbed the Access to Oncology Medicines (ATOM) coalition, the project will formally launch alongside the World Health Assembly, taking place this weekend in Geneva, Switzerland.

ATOM is being led by the Union for International Cancer Control (UICC), together with multiple partners in the life scienced from industry and academia, including the American Society for Clinical Oncology (ASCO), AstraZeneca (LSE: AZN), Novartis (NOVN: VX) and Roche (ROG: SIX).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical